Payment overview · 2025
General Payments
$576.79
18 reported records · 5 companies
Healthcare provider profile · identity verified
Pascal P Bordy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT CHARLOTTE, FL · NPI 1952514283
Verified facts
What the public records show
CMS Open Payments records show Pascal P Bordy, M.D. received $576.79 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $280.57 | 48.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.08 | 34.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.21 | 10.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.50 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.43 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.79 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $242.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $196.08 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $139.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.23 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.81 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 107 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 305 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 66 |
| Gabapentin | Gabapentin | 180 | 33 |
| Prednisone | Prednisone | 173 | 85 |
| Alprazolam | Alprazolam | 167 | 38 |
| Lisinopril | Lisinopril | 164 | 59 |
| Metformin Hcl | Metformin Hcl | 152 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 50 |
| Losartan Potassium | Losartan Potassium | 143 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 26 |
| Omeprazole | Omeprazole | 119 | 38 |
| Simvastatin | Simvastatin | 116 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 17 |
| Trazodone Hcl | Trazodone Hcl | 66 | 21 |
| Potassium Chloride | Potassium Chloride | 65 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Furosemide | Furosemide | 61 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 61 | suppressed |
| Allopurinol | Allopurinol | 58 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 16 |
| Tramadol Hcl | Tramadol Hcl | 55 | 11 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Eliquis | Apixaban | 51 | 15 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Glipizide Er | Glipizide | 50 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 18 |
| Azithromycin | Azithromycin | 47 | 40 |
| Xtampza Er | Oxycodone Myristate | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 33 |
| Farxiga | Dapagliflozin Propanediol | 44 | 14 |
| Meloxicam | Meloxicam | 44 | 15 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 43 | 31 |
| Cephalexin | Cephalexin | 40 | 28 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Linzess | Linaclotide | 39 | 11 |
| Ozempic | Semaglutide | 39 | 12 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Atenolol | Atenolol | 32 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Glipizide | Glipizide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $576.79 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, OTEZLA, Ozempic, REPATHA, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error